These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 5469783)

  • 1. Coumermycin A-biopharmaceutical studies. I.
    Newmark HL; Berger J
    J Pharm Sci; 1970 Sep; 59(9):1246-8. PubMed ID: 5469783
    [No Abstract]   [Full Text] [Related]  

  • 2. Coumermycin A1-Biopharmaceutical studies. II.
    Newmark HL; Berger J; Carstensen JT
    J Pharm Sci; 1970 Sep; 59(9):1249-51. PubMed ID: 5469784
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic profile of coumermycin A.
    Kaplan SA
    J Pharm Sci; 1970 Mar; 59(3):309-13. PubMed ID: 5416168
    [No Abstract]   [Full Text] [Related]  

  • 4. Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients.
    Batchelor HK; Kendall R; Desset-Brethes S; Alex R; Ernest TB;
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):833-42. PubMed ID: 23665448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paediatric oral biopharmaceutics: key considerations and current challenges.
    Batchelor HK; Fotaki N; Klein S
    Adv Drug Deliv Rev; 2014 Jun; 73():102-26. PubMed ID: 24189013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships in chemically modified coumermycin.
    Keil JG; Godfrey JC; Cron MJ; Hooper IR; Nettleton DE; Price KE; Schmitz H
    Pure Appl Chem; 1971; 28(4):571-601. PubMed ID: 5004168
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBPK models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Aarons L; Bergstrand M; Bolger MB; Galetin A; Hatley O; Jamei M; Lloyd R; Pepin X; Rostami-Hodjegan A; Sjögren E; Tannergren C; Turner DB; Wagner C; Weitschies W; Dressman J
    Eur J Pharm Sci; 2014 Jun; 57():300-21. PubMed ID: 24060672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oral absorption of doxycycline by man.
    von Wittenau MS
    Int Z Klin Pharmakol Ther Toxikol; 1969 Jan; 2(1):52-5. PubMed ID: 4979040
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effectivness prolongation of drugs with special consideration for peroral depot drug forms].
    Hänselmann B; Voigt R
    Pharmazie; 1971 Feb; 26(2):57-77. PubMed ID: 4930108
    [No Abstract]   [Full Text] [Related]  

  • 11. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the feasibility of oral controlled release in an exploratory development setting.
    Thombre AG
    Drug Discov Today; 2005 Sep; 10(17):1159-66. PubMed ID: 16182208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semisynthetic coumermycins: structure-activity relationships.
    Price KE; Chisholm DR; Godfrey JC; Misiek M; Gourevitch A
    Appl Microbiol; 1970 Jan; 19(1):14-26. PubMed ID: 5415210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.
    Shen H; Zhong M
    J Pharm Pharmacol; 2006 Sep; 58(9):1183-91. PubMed ID: 16945176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced absorption of digitoxin from orally administered digitoxin-polyvinylpyrrolidone coprecipitates.
    Stupak EI; Bates TR
    J Pharm Sci; 1973 Nov; 62(11):1806-9. PubMed ID: 4758077
    [No Abstract]   [Full Text] [Related]  

  • 17. A modified physiological BCS for prediction of intestinal absorption in drug discovery.
    Zaki NM; Artursson P; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1478-87. PubMed ID: 20734997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of phosphonomycin after oral administration in man.
    Foltz EL; Wallick H; Rosenblum C
    Antimicrob Agents Chemother (Bethesda); 1969; 9():322-6. PubMed ID: 5396508
    [No Abstract]   [Full Text] [Related]  

  • 19. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative biopharmaceutical study of tegalide].
    Lopatina NB; Lebedeva MN
    Med Parazitol (Mosk); 2000; (1):27-9. PubMed ID: 10808715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.